Emerging clinical evidence suggests that Novera Retatrutide, a twin-action medication from Novo Nordisk, could offer a substantial step in weight loss. Beyond many existing options, Retatrutide affects both glucagon-like peptide-1 (GLP-1) and the GIP hormone, potentially producing to improved los